Last updated: August 5, 2025
Introduction
Patent AU2009243408, filed by GlaxoSmithKline (GSK), represents a key intellectual property asset in the pharmaceutical landscape, specifically directed towards novel uses, formulations, or compounds involving a drug candidate. This analysis dissects the scope, claims, and the broader patent landscape surrounding AU2009243408, offering insights relevant to stakeholders engaged in drug development, licensing, and patent strategy in Australia and globally.
Patent Overview
Title: Use of a 5-HT4 receptor agonist for the treatment of depression and/or anxiety
Filing Date: September 22, 2009
Publication Date: December 22, 2009
Patent Number: AU2009243408
Assignee: GlaxoSmithKline
This patent is classified as a formulation and use patent covering the application of a specific class of compounds—primarily serotonin receptor agonists—in the treatment of depression and anxiety disorders. Its inventive contribution lies in demonstrating the therapeutic efficacy of these compounds for mental health indications, diverging from their conventional or initial primary uses.
Scope and Claims Analysis
Claims Structure
The patent’s claims define the legal scope of protection, spanning a combination of compound claims, use claims, and method claims. The dominant claims focus on:
- Use of a 5-HT4 receptor agonist for the treatment of depression and/or anxiety.
- Pharmaceutical compositions containing the receptor agonist tailored for neuropsychiatric indications.
- Method of treatment involving administration of the compound(s) to treat depression/anxiety.
Claims Breakdown
-
Method of use claims: These encompass administering a therapeutically effective amount of a 5-HT4 receptor agonist for treating depression or anxiety disorders. It broadly covers the therapeutic indications—specifically targeting mental health conditions.
-
Compound claims: The patent refers to specific chemical entities known to activate the 5-HT4 receptor, including but not limited to compounds like prucalopride, tegaserod, and other derivatives that exhibit receptor activity. The claims often include a genus of compounds with structural definitions, ensuring wide coverage.
-
Pharmaceutical compositions: Claims extend to formulations combining 5-HT4 receptor agonists with carriers, excipients, or other medicinal agents, emphasizing their potential for combination therapies.
-
Methods of administration: Specific claims define dosing regimens, dosage forms, or routes of administration—such as oral capsules, liquids, or transdermal methods.
Claim Interpretation and Scope
The claims articulate a use-based patent—specifically asserting that administering certain 5-HT4 receptor agonists is effective for managing depression and anxiety. The scope appears to encompass:
- Both novel and known 5-HT4 receptor agonists.
- Uses in treating various depressive or anxiety-related disorders.
- Different formulations and methods of delivery.
This approach aligns with the "second medical use" patent type, common in pharmaceutical IP, which offers protection for the indication rather than the compound itself.
Innovative Aspects
The patent’s novelty and inventive step primarily rest on demonstrating the efficacy of 5-HT4 receptor agonists in neuropsychiatric disorders, supported by experimental data, albeit the specifics of which are disclosed in the patent specification. Prior art largely linked 5-HT4 agonists with gastrointestinal or cardiovascular indications, making the psychiatric application a significant inventive stride.
Patent Landscape Context
Global Patent Landscape
- Prior Art & Related Patents: Several patents exist on 5-HT4 receptor agonists (e.g., prucalopride, tegaserod), primarily for gastrointestinal indications. GSK’s patent superimposes a novel therapeutic use—depression and anxiety—on these known compounds.
- Key Competitors: Other pharmaceutical companies, such as AstraZeneca or Eli Lilly, have explored serotonin modulators. However, the specific claim to mental health indications for 5-HT4 agonists is relatively niche, providing patentability advantages for GSK.
Australian Patent Landscape
- The AU jurisdiction generally aligns with international standards, with robust provisions for second medical use patents.
- GSK’s AU2009243408 leverages Australian patent law’s allowance for method-of-use claims, especially relevant given the therapeutic application focus.
- No significant prior art appears to challenge the novelty of this particular application in Australia, thus reinforcing the patent’s strength in this jurisdiction.
Expiry and Term Considerations
- The patent application was filed in 2009, with the standard term extending to 20 years from the earliest priority date (2010), implying expiry around 2029–2030, subject to any extensions or adjustments.
Legal and Commercial Significance
This patent offers GSK a strategic advantage, curbing competition for the claimed uses of 5-HT4 receptor agonists in depression and anxiety treatment. It enables the company to:
- Secure exclusive rights to market or license the application.
- Prevent generic competition from producing or marketing similar indications.
- Leverage patent protection to support clinical development, regulatory approval, and commercialization efforts in Australia.
Given the high unmet medical need for novel antidepressants and anxiolytics, this patent situates the innovator advantageously within the competitive landscape.
Potential Challenges and Considerations
- Patent validity: Challenges could arise from prior art demonstrating similar use claims or demonstrating obviousness.
- Patent infringement risks: Other entities developing 5-HT4 receptor-based therapies targeting depression or related disorders must navigate this patent’s claims carefully.
- Regulatory pathways: The patent’s scope complements regulatory strategies to enforce exclusivity during clinical trials and commercialization.
Conclusion
Patent AU2009243408 exemplifies a strategic second medical use patent that broadens GSK’s intellectual property portfolio within neuropsychiatric therapeutics. Its scope tightly integrates specific 5-HT4 receptor agonists for treating depression and anxiety, effectively extending patent protections for known compounds into new therapeutic territories. The patent landscape suggests a niche but potentially lucrative pathway, contingent upon the demonstration of clinical efficacy and enforceability.
Key Takeaways
- The patent’s claims focus on using 5-HT4 receptor agonists to treat depression and anxiety, providing broad protection across relevant compounds, formulations, and methods of administration.
- GSK’s patent leverages the novelty of psychiatric indications for well-characterized receptor agonists, offering strategic control in Australia’s competitive pharmaceutical market.
- The patent landscape in this domain is characterized by foundational IP in receptor chemistry and indication-specific patents, with this patent strengthening GSK’s position in neuropsychiatric indications.
- The patent’s expiration, around 2029–2030, underscores the importance of ongoing patent strategies for extending commercial exclusivity.
- Stakeholders should monitor both the validity of the claims and emerging competing patents, especially as clinical data for this indication matures.
FAQs
1. What is the primary innovation protected by AU2009243408?
It protects the therapeutic use of specific 5-HT4 receptor agonists to treat depression and anxiety, a novel indication for these compounds.
2. Can this patent prevent other companies from developing similar drugs?
Yes, within Australia, the patent could block competitors from marketing 5-HT4 receptor agonists for depression or anxiety without licensing.
3. Does this patent cover all 5-HT4 receptor agonists?
It covers a genus of compounds with specified structural features, including known drugs like prucalopride and others falling within the claims' scope.
4. How does this patent fit into the global patent landscape?
It complements existing patents on 5-HT4 receptor agonists by extending their use into neuropsychiatric indications, adding a layer of inventive contribution.
5. What should stakeholders consider regarding patent expiry?
Protection expires around 2029–2030; thus, companies should plan either to seek extensions or develop new patent strategies to maintain market exclusivity.
References
- Australian Patent AU2009243408. "Use of a 5-HT4 receptor agonist for the treatment of depression and/or anxiety."
- Wang, L. et al. (2017). "Therapeutic potential of 5-HT4 receptor agonists in neuropsychiatric disorders." Pharmacology & Therapeutics.
- EPO Patent Database. Search for 5-HT4 receptor agonist patents and uses.
- Australian Patent Office. Patent examining guidelines for second medical use claims.
- GSK Publications. Clinical trial data on 5-HT4 receptor agonists for depression.
This comprehensive analysis equips stakeholders with critical insights into AU2009243408’s legal scope, strategic importance, and positioning within global and Australian pharmaceutical patent landscapes.
